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Abstract
Objectives
To elucidate new risk factors for MRSA carriers without known risk factors (MRSA of
unknown origin; MUO). These MUO carriers are neither pre-emptively screened nor isolated
as normally dictated by the Dutch Search & Destroy policy, thus resulting in policy failure.
Methods
We performed a prospective case control study to determine risk factors for MUO acquisi-
tion/carriage (Dutch Trial Register: NTR2041).
Cases were MUO carriers reported by participating medical microbiological laboratories
to the RIVM from September 1st 2011 until September 1st 2013. Controls were randomly
selected from the community during this period.
Results
Significant risk factors for MUO in logistic multivariate analysis were antibiotic use in the last
twelve months, aOR 8.1 (5.6–11.7), screened as contact in a contact tracing but not
detected as a MRSA carrier at that time, aOR 4.3 (2.1–8.8), having at least one foreign par-
ent, aOR 2.4 (1.4–3.9) and receiving ambulatory care, aOR 2.3 (1.4–3.7). Our found risk
factors explained 83% of the MUO carriage.
Conclusions
Identifying new risk factors for MRSA carriers remains crucial for countries that apply a tar-
geted screening approach as a Search and Destroy policy or as vertical infection prevention
measure.
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Introduction
In The Netherlands MRSA prevalence is low, measured at 0.12% at hospital admission in 2005–
2007[1] and 0.8% in Dutch outpatients in the Dutch-German border region in 2012.[2] Among
S.aureus blood-cultures the MRSA prevalence was 1.0% (24/2,386).[3] To keep MRSA preva-
lence low, prudent use of antibiotics is instigated and a Search and Destroy policy (S&D) is in
place. S&D consists of screening of defined risk patients (Table 1) at hospital admission, and by
pre-emptive isolation of them pending the screening results.[4] Colonized patients and health-
care workers are treated with strict treatment regimens to eradicate the carriage of MRSA. [4]
One of the revisions on MRSA risk groups, was due to the discovery of livestock-associated
MRSA with sequence type 398 (LA-MRSA ST398) in The Netherlands.[5] The risk groups for
S&D were subsequently updated with pig and veal calf farmers. In 2016, LA-MRSA accounted
for 26% (892/3,478) of MRSA isolates.[3]
Apart from the discovery of LA-MRSA, it appeared that the proportion of reported MRSA
without known risk factors, thus not defined as risk patients, became substantial. In 2008–
2009, 25% (1350/5545) of all MRSA were reported as MRSA without known risk factors [6] In
2016, this has increased to 38% (810/2,121). [3] The MRSA without known risk factors were
named MRSA of Unknown Origin or MUO. MUO are per definition unexpected and are
mostly detected in clinical samples. However, in screening samples on MRSA, MUO can be
detected as well. This is the case when the found MRSA genotype does not match the MRSA
genotype of the index person.[6]
We started a nation-wide study to explore the risks and causes of MUO, so the defined risk
groups in S&D policy can be updated and unnoticed dissemination of MRSA in healthcare set-
tings and the community can be stopped. In this paper, we report the results from our prospec-
tive case control study to determine the risk factors for carriage of MUO.
Methods
MRSA surveillance
In the Netherlands, all MRSA are detected either through active surveillance screening or in a
clinical sample and are mandatorily sent to the Dutch National Institute for Public Health and
the Environment (RIVM). Yearly, around 3,000 isolates are submitted to the RIVM.[7] Along
with the isolate, risk factors for MRSA carriage, as defined in the MRSA guideline by the Dutch
Working party on Infection Prevention (WIP), are reported to the RIVM by standard question-
naire.[8, 9] Any person detected with MRSA and reported with one or more risk factors as
described in this WIP guideline is defined as MRSA of Known Origin (MKO). Any person
detected with MRSA lacking these risk factors, is defined as MRSA of Unknown Origin (MUO).
Trawling study
A trawling questionnaire was forwarded by Dutch Medical Microbiological Laboratories
(MML) in 2010 to all MUO carriers reported to the RIVM in 2009. The retrospective trawling
questionnaire was set-up to learn which risk factors could be involved with MUO to narrow
and specify the number and kind of questions in the case control questionnaire, as well to
choose the best control group for the case control study. To prevent recall bias, the maximum
timespan for events in the past that had to be recalled by trawling study participants was lim-
ited to two years.
To confirm that these MUO carriers were not misclassified MKO carriers, the question-
naire included questions on the described risk factors for MRSA in the Dutch WIP guideline
on MRSA (Table 1). Furthermore, the questionnaire included questions on occupations,
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Table 1. Risk categories in the Dutch WIP guideline on MRSA.
January 2007 (updated: March 2008) December 2012
Patients Healthcare workers Patients Healthcare workers
Category 1 Category 1 Category 1 Category 1
- Proven carrier status of MRSA - Proven carrier status of MRSA - Proven carrier status of MRSA - Proven carrier status of MRSA
- Follow-up after MRSA eradication
therapy (3 follow-up culture-sets)
- Follow-up after MRSA eradication
therapy (3 follow-up culture-sets)
- Undergoes MRSA eradication
treatment
Category 2 Category 2 Category 2 Category 2
- Nursed < 2 months > 24h in a
foreign hospital
- Unprotected contact with MRSA
carrier
- < 2 months ago unprotected contact
with MRSA carrier inside (as part of
contact tracing) or outside
(household members, partners,
caretakers of MRSA carriers) the
hospital
- Nursed < 2 months > 24h in a
foreign care facility
- Nursed < 2 months < 24h in a
foreign hospital with the
following risk factors at arrival in
a Dutch hospital: operation,
infection, catheter or drains
present
- Hospitalized < 2 months ago in a
foreign hospital, were operated
abroad, received a drain or
catheter, were intubated, have
skin lesions or possible infectious
sources such as abscesses or
furuncles.
- Nursed < 2 months < 24h in a
foreign care facility with at least
one of the following risk factors:
operation abroad, chronic
infection or persistent skin
lesions, presence of abscesses or
furuncles at hospitalization in the
Netherlands.
- Patient from department
(hospital or nursing home) with
an ongoing MRSA outbreak
- Nursed < 2 months < 24h in a foreign
care facility with at least one of the
following risk factors: operation
abroad, chronic infection or
persistent skin lesions, presence of
abscesses or furuncles at
hospitalization in the NL.
- Adopted children regularly
hospitalized or visiting the
hospital
- Foreign patient at dialysis unit - Foreign dialysis patients
- Share a room with unexpected
MRSA carrier
- Stayed < 2months ago in a Dutch
care facility (unspecified) with an
ongoing MRSA outbreak on the
department
- After MRSA eradication therapy
but before follow-up culture-sets
are taken
- Adopted children from abroad living
in the Netherlands
- Contact with live pigs or veal
calves
- Contact with industrial, live pigs, veal
calves or broiler chickens regardless
whether this contact was
professional or not, and/or lives on
such a farm.
Category 3 Category 3 Category 3 Category 3
- Dutch dialysis patients dialyzed
abroad
- Protected contact with MRSA
carriers
- Unprotected contact with MRSA
positive HCW < 2 months ago
- Persistent exposure with a
negative MRSA test less than
three months ago.
- First year after MRSA
eradication therapy with MRSA
negative follow-up culture-sets
- < 2 months ago worked abroad
>24h in a hospital or nursing
home
- Dutch dialysis patients dialyzed
abroad < 2 months ago
- Unprotected contact with MRSA
positive patient < 2 months ago
inside or outside the hospital
- Nursed > 2 months in foreign
hospital with persistent skin
infections or risk factors
- First year after MRSA eradication
therapy with MRSA negative
follow-up culture-sets
- Nursed > 2 months in foreign
hospital with persistent skin
infections or risk factors
- < 2 months ago > 24h patient-
related activities in a foreign care
facility
- First year of follow-up after MRSA
eradication therapy and the first
three negative follow-up culture-sets
- Guided patients < 2 months ago
from a foreign to a Dutch care
facility without isolation
precautions
- Persistent exposure with a negative
MRSA test less than three months
ago.
- Carrier with uncomplicated MRSA
who was negative before the start
of MRSA eradication therapy
Category 4 Category 4 Category 4 Category 4
(Continued )
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sports, leisure, social habits and lifestyles, and risk factors in other populations described in the
literature. (PubMed at 01-01-2010, search keywords ‘MRSA’ and ‘risk factor’).
Excluded cases were non-responders, the deceased, potential cases that lacked an address or
were misclassified as MKO for various reasons. Included cases were all MUO carriers not mis-
classified as MKO upon return of the questionnaire.
Questionnaire data was analysed as described under ‘statistics’, and the results were inter-
preted to update the questionnaire and define the best controls.
Case control study
Study population. The study population consisted of patients detected with MRSA but
without known risk factors (MUO) and population controls. The sample site and frequency of
detection was not taken into account. In the Netherlands, persons detected with MRSA are all
included in the national MRSA database, regardless of sample site, infection or indication for
sampling.
To determine the risk factors for MUO, we approached cases and controls with question-
naires (S1 Text). Case control study participants who answered95% questions of the total of
43 questions and of whom informed consent was obtained, were rewarded with 25 euros and
enrolled as case or control.
To detect an odds ratio (OR) of 2 or higher with 80% power and an alpha of 0.05, we aimed
to enrol 500 cases and 1,000 controls (1:2 case-control ratio), based on an estimated 700 MUO
reported to the MRSA surveillance in two years (on a total of ±3,000 MRSA carriers reported
per year).
Case definition. Potential cases were MRSA carriers, reported by the participating MML
(medical microbiologist or infection prevention personnel) as MUO to the RIVM for the
MRSA surveillance from September 1st, 2011 until September 1st, 2013. Before sending the
questionnaire, assumed MUO cases were checked on the following exclusion criteria: death,
lack of address or misclassification (of a MKO as a MUO). Upon return of the questionnaire,
we checked once more for misclassification. True MUO were included as case.
Control definition. Selecting the right controls was based on the results from the trawling
study (see results below). The best control group was considered to be unmatched community
Table 1. (Continued)
January 2007 (updated: March 2008) December 2012
Patients Healthcare workers Patients Healthcare workers
- Nursed > 2 months ago in a
foreign hospital without
persistent skin lesions or risk
factors
- Successful MRSA eradication
therapy > 1 year ago. Follow-up
culture-sets remained MRSA
negative
- None of the above categories applies - None of the above categories
applies
- Stayed < 24h in a foreign
hospital without risk factors or
operations
- Negative follow-up culture-set
after protected contact with
MRSA carrier
- On a department with MRSA
where adequate precautions
were taken
- Negative follow-up culture-sets
a year after MRSA eradication
therapy ended
HCW: Healthcare worker. For the trawling and case control questionnaires, the risk categories of the 2007–2008 WIP guideline were used. In 2015, the
RIVM added as risk factor a refugee visiting a Dutch hospital who had been in a refugee camp less than two months before (category 2/3).
https://doi.org/10.1371/journal.pone.0188502.t001
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controls. This choice was based on the fact that the MUO were selected from the RIVM data-
base, which contained not only MRSA carriers detected at hospitals, but also those detected by
general practitioners or in long-term care facilities. Furthermore, MUO carriers were shown
to be a diverse group of carriers.
The controls were randomly chosen from 60 Dutch municipalities from all over of The
Netherlands. These 60 municipalities were a national representative subset of all 415 munici-
palities in The Netherlands, and contained large, middle and small municipalities.
Inclusion procedure. Every two weeks a printout was made in Microsoft Excel of the
newly reported MUO to the RIVM. Questionnaires for MUO carriers were sent to participat-
ing MML (S1 Text). The MML checked the carriers on exclusion criteria before forwarding
the questionnaires to the MUO carriers.
After three weeks, non-responders were once again approached by questionnaire or by tele-
phone. Returned questionnaires of both cases and controls were checked to exclude any MKO
carriers misclassified as MUO. Misclassifications were not included as cases.
Controls were sent a questionnaire by mail. After three weeks non-responders were
approached once more by mail or if possible by telephone.
This study was approved by the medical ethical committee at the Erasmus MC and regis-
tered in the Dutch Trial Register under NTR2041. Written informed consent was requested
from both cases as controls, before participating in this study by questionnaire. Data were
aggregated and anonymized before analysis.
Statistics. Questionnaire data were analysed with SAS Enterprise Guide (version 4.2 by
SAS Institute Inc., North Carolina, USA), using descriptive, univariate (2x2 tables and Fisher’s
Exact test) and multivariate analysis (multiple regression logit model, backward elimination
with significance level of 0.05 to stay in the model, with and without dummy variables).
Results
Trawling study
Of the reported 794 MUO to the MRSA surveillance, only 277 fulfilled inclusion criteria and
could be approached by questionnaire through participating MML (Fig 1). Of these 37% (104/
277) responded and all age groups were present. Of the 104 returned questionnaires, 22 were
MKO, and thus misclassified as MUO and the remaining 82 were MUO.
Fig 1. Flowcharts for trawling and case control studies.
https://doi.org/10.1371/journal.pone.0188502.g001
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Fifty-two percent (43/82) of MUO carriers were male and none of the MUO were health-
care workers. Sixty-six percent (54/82) of MUO were patients detected in the hospital. How-
ever the other MUO carriers were detected by general practitioners or community-based
healthcare institutions other than hospitals.
Case control study
Between September 1st 2011 and September 1st 2013 1,455 MUO were reported to the RIVM
and 767 MUO were approached by questionnaire (Fig 1). The response rate among cases was
49% (376/767), that of controls 33% (667/2,000). Of the 376 returned questionnaires, 38%
(144/376) of cases turned out to be MKO, thus misclassified as MUO, leaving 232 cases for
analyses. None of these 232 cases were healthcare workers.
Comparing 232 cases with 667 controls, some risk factors, such as hospitalization of a
household member, chronic disease, and carriage of ST398 MRSA without professional con-
tact with pigs/veal calves or other farm animals, were significant in univariate analysis, but not
in the final regression model (Table 2).
Significant factors in the multivariate logistic regression model were antibiotic use in the
last twelve months aOR 8.1 (95%CI 5.6–11.7), screened as contact in a contact tracing but not
detected as a MRSA carrier at the time aOR 4.3 (95%CI 2.1–8.8), having at least one foreign
parent aOR 2.4 (95%CI 1.4–3.9), and receiving ambulatory care aOR 2.3 (95%CI 1.4–3.7).
The most frequently used antibiotics by cases and controls were ß-Lactam-antibiotics. There
was no significant difference (p = 0.9) between cases and controls for ß-Lactam-antibiotics use
in general, although there was a significant (OR 5.7; 95%CI 1.4–23.1) difference for the use of
Amoxicillin/clavulanic acid (13.2% among cases (7/53) versus 2.6% (3/116) among controls).
Among ambulatory care use, home care was the most common, and MUO carriers were
significantly more exposed (OR 3.3; 95%CI 1.5–6.9) to it.
Eighty-three percent of all MUO could be explained by the found independent risk factors
in multiple regression model. (Table 3).
Discussion
We identified the following independent risk factors for MUO: antibiotic use in the preceding
12 months, receiving ambulatory care, and being screened for MRSA in contact tracing but
Table 2. Multivariate logistic regression for MUO risk factors.
Risk factor MUO
(n = 232)
Controls
(n = 667)
p-value aORa 95%CI
ST398 but without professional contact with pigs/veal calves or other farm animals* 18 0 n.s. 1.8 (0.6–5.2)
Hospitalization within householdb 84 157 n.s. 1.1 (0.7–1.7)
Chronic disease 85 135 n.s. 1.4 (0.9–2.0)
Antibiotic use in last 12 months 150 139 < 0.01 8.1 (5.6–11.7)
Screened as part of a contact tracing but not found to be a MRSA carrier at the time 24 23 < 0.01 4.3 (2.1–8.8)
At least one foreign parent 48 71 < 0.01 2.4 (1.4–3.9)
Ambulatory care received 55 66 < 0.01 2.2 (1.4–3.7)
aOR: adjusted Odds Ratios; CI: Confidence Interval
* before 2012 only professional contact to pigs/veal calves was a risk factor. After 2012 any contact to pigs, veal calves and broiler chickens became a risk
factor. But presence on a farm is not a risk factor per se, unless at the farm they have pigs, veal calves or broiler chickens.
aLogistic regression model with backward elimination containing the following factors: no professional contact with pigs/veal calves or other farm animals,
antibiotic use in the preceding 12 months, chronic disease, not detected with contact tracing, at least one foreign parent, hospitalization within the
household and ambulatory care. The R2max of the model was 0.29, while the AUC was 0.79.
bThese factors were univariate significant, as well as possible confounders for receiving ambulatory care.
https://doi.org/10.1371/journal.pone.0188502.t002
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not having been detected at the time. Travelling abroad was not a risk factor, although we
found a significant association with having a foreign parent.
In literature, antibiotic use in the last twelve months has been described before as risk factor
for the general population; as a risk factor for MRSA carriage in children [10, 11], and within
households where carriers were present [12]. Also, a systematic review showed a association
between antibiotic exposure to quinolones, glycopeptides, cefalosporins and beta-lactams and
an increased risk of MRSA isolation in adults.[13, 14] These former findings were confirmed
by our study, as we found a significant difference in amoxicillin/clavulanic acid use between
cases and controls. Greater use of amoxicillin/clavulanic acid may be due to more infections
among MUO carriers compared to the controls. We cannot rule out this possibility as we did
not measure the number of infections among MUO, since submission of an infection isolate to
the MRSA database is preferred but not obliged. The Netherlands has the lowest use of all anti-
biotics in the European Union. In 2013, 2015 and 2017, it was 10.8, 10.7 and 10.4 defined daily
doses/1000 inhabitants/day respectively.[3, 15]
Interestingly, having been screened as part of a contact tracing in the past, but not detected
at that time, was a significant risk factor for MUO carriage. This is an important risk factor for
countries with S&D policy, as this policy aims to identify all people at risk, including contacts.
Explanations for this risk factor could be a too low sensitivity of MRSA culture, missing sam-
pling sites, or when sampling occurs too early after exposure, and is not follow-upped with
repeated sampling. For this reason it is also recommended to sample healthcare workers on
start of their next duty instead of immediately after unprotected contact with a MRSA carrier.
The current guideline indicates one set of samples from nose, throat, rectum and wounds
when present. The guidelines assumes a sampling frequency of one set to be sufficient. There
are no indications in the guideline on the timing of sampling of contacts after exposure when
tracing MRSA contacts. Indeed, in our previous study we showed that carriage is not always
detectable in each sample moment when sampling after MRSA eradication therapy to monitor
Table 3. Risk factors for MUO.
Risk factors MUO
(%; n = 232)
All cases with the risk factor:
Antibiotic use in the last 12 months 150 (64.7)
Screened as part of a contact tracing but not found to be a MRSA carrier at the time 24 (10.3)
At least one foreign parent 48 (20.7)
Ambulatory care received 55 (23.7)
Number of cases that only have this one risk factor
Antibiotic use in the last 12 months 52 (22.4)
Screened as part of a contact tracing but not found to be a MRSA carrier at the time 5 (2.2)
At least one foreign parent 8 (3.4)
Ambulatory care received 6 (2.6)
Number of cases that only have one risk factor 71 (30.6)
Number of cases with a combination of 2 or more of the above risk factors 121 (52.2)
Total cases of MUO explained by these risk factors 192 (82.8)
Remaining unexplained MUO 40 (17.2)
MUO carriers had a single risk factor in 30.6% (71/232) and had in 52.2% multiple risk factors. Among those
MUO with a single significant risk factor, antibiotic use in last twelve months accounted for 22.4%, at least
one foreign parent for 3.4%, ambulatory care received for 2.6%, and screened as part of a contact tracing
but not found to be a MRSA carrier at the time for 2.2%.
https://doi.org/10.1371/journal.pone.0188502.t003
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MRSA recurrence.[16] Further studies on reliability of contact tracing should be conducted,
especially in regards to the number and sample sites of cultures when screening for contacts.
Having at least one foreign parent, was also one of the significant risk factors. Possibly, an
immigration background from countries with a higher MRSA prevalence may result in a
higher exposure to MRSA by visiting or close contact within the family. Especially those coun-
tries with higher levels of CA-MRSA. This is in line with findings from Denmark which
showed 40% of affected individuals CA-MRSA infections with certain CA-MRSA clones had a
positive family history related to foreign regions where such clones were predominant. [17]
Furthermore, the MRSA prevalence among actively screened asylum seekers (refugees/immi-
grants) in The Netherlands was 9.7% (87/898). [18] Similar to findings in Germany, but much
higher than the prevalence in the general population at hospital admission.[18, 19] In 2015,
the RIVM added as risk factor a refugee visiting a Dutch hospital who had been in a refugee
camp less than two months before (category 2/3).[20] It is possible that a limited understand-
ing of the Dutch language prevented refugees from participating. If this is the case then our
aOR for having at least one foreign parent, is an underestimation. Our national MRSA data-
base currently contains spa, MLVA and PVL data. But this typing data, along with scarce epi-
demiological data, is currently not sufficient to link MUO to outbreaks abroad or transmission
or sources occurring outside a Dutch health care centre. Furthermore, in this study we did not
analyse the typing data, including PVL. As we did so in a previous study, and learned that PVL
positive MRSA isolates were significantly larger among MUO than among MKO.[6]
Ambulant or home care exposure are scarcely published in literature as risk factor for
MRSA carriage, as only ambulatory care facilities in Germany were described and designated
as a reservoir for dissemination.[21] Theoretically, transmission of MRSA through ambulatory
care could be possible, thus creating new MUO carriers. This finding necessitates further
investigation in the future in The Netherlands, as ambulatory care facilities are becoming
more important in a population with a growing segment of the elderly.
The use of arbitrary cut-offs in risk factor definitions could theoretically result in MUO.
However, after multivariate analysis we found no significant risk factors related to arbitrary
cut-offs in risk factor definitions, such as ‘less than two months ago’ in case of a visit to a hospi-
tal abroad.
We could not confirm poultry consumption or scuba gear sharing as risk factors as found
in the study by van Reijen et al.[22] Possible explanations for the difference could be due to
design, different selection and inclusion criteria of cases and controls, difference in question-
ing, and the number and selection of participating MML. Continuous analyses of MUO and
its risk factors in the future will be necessary, not only to measure the effect of new policy
implementation, but also to elucidate differences in outcome between studies.
Two risk factors published in recent years, fine air particles for Cystic Fibrosis (CF) patients
and livestock-density for livestock-associated MRSA, were not included in our case control
questionnaire.[23, 24] However, we think the impact of the absence of these risk factors in the
questionnaire is minimal.
The use of standardized questionnaires, representative nationwide participation and com-
munity controls were study strengths which allows us to generalize results for all MUO in The
Netherlands. Due to low national MRSA prevalence at hospital entry,[1] the odds of including
MRSA carriers among the controls were very low.
The confines of the MRSA surveillance database, the lack of exact data on infection/car-
riage, the necessity to contact and possible recall bias were limitations of our study.
We aimed to enrol 500 cases and 1,000 controls based on an estimation of 700 MUO per
two years to detect odds ratios of two or higher with 80% power. Inclusion of MUO was more
difficult due to misclassification of some MUO and a lower willingness to participate in the
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study than expected. We therefore ended up including 232 cases and 667 controls, which was
still enough to detect OR of 2 or higher with an 80% power and an alpha of 0.05, due to a larger
number of controls per case.
In the trawling questionnaire study, as well as in the case control study, we found there
was misclassification of MKO as MUO, inflating the number of MUO in the MRSA surveil-
lance. In the future, more effort is needed to detect the presence of risk factor before classifying
a carrier as MUO, and thus registration of MKO or MUO in the RIVM database should be
improved to reduce the number of misclassified MUO. Currently, 38% of total reported
MRSA are reported as MUO[3, 7], underlining its significance. Even after correction for mis-
classification, MUO is estimated to be a fourth of total MRSA reported to the surveillance each
year.
Some of the newly defined risk factors, such as antibiotic use, can be common (Table 2)
and would have low specificity when included into S&D risk groups. Other risk factors, such
as being part of contact tracing in the past, could result in changes to the national guideline in
regards to sampling frequency and timing. To determine the probability of MRSA carriage
more precisely in the future, the known risk factors (current ones in the WIP guideline and
from this study) should be analysed by creating risk tables or an algorithm. The presence of a
single or combined risk factors could thus lead to targeted action such as screening or screen-
ing in combination with isolation on admission. Such a probability analysis could be subject of
a next study.
For countries that apply a S&D approach as vertical infection prevention approach, MUO
identification and elucidation is important. In a targeted screening approach as in S&D, per-
sons at risk for MRSA carriage are identified (targeted) by means of risk factors. Monitoring
MRSA is necessary to evaluate the effect of policy adjustments and any epidemiological
changes that may give rise to new risk factors. Antibiotic use in the preceding 12 months,
receiving ambulatory care and having at least one foreign parent, are common risk factors
with limited practicality, but could still prove useful when combined to determine the proba-
bility of MRSA carriage risk based on a risk table and algorithm.
In conclusion, risk factors for MUO were mainly healthcare related despite MUO carriers
not always being hospital-associated. Our new risk factors elucidated 83% of MUO, bringing
us a step closer to preventing MUO from undermining successful S&D policy.[25]
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